Clinical Trials

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Mantle-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03697356 2023-10-06

Ballondor

Phase 2 Recruiting

54 enrolled

Waldenstrom Macroglobulinemia

NCT00571493 2023-09-28

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Phase 1/2 Completed

42 enrolled 8 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT04224571 2023-08-30

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

208 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01267812 2023-07-27

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

23 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT02840539 2023-03-20

BATMAN

19 enrolled

Lymphoma, Mantle-Cell

NCT02356458 2022-03-11

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1/2 Terminated

58 enrolled

Lymphoma, Neoplasms, Recurrence, Lymphoma, Mantle-Cell

NCT00477412 2022-01-28

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Phase 1/2 Completed

107 enrolled 14 charts

Lymphoma, Mantle-Cell

NCT02613598 2021-12-20

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Phase 1 Completed

15 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT00479167 2021-11-04

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Phase 2 Terminated

1 enrolled 1 chart

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01592981 2021-06-18

R2W

60 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Waldenstrom Macroglobulinemia

NCT02037256 2021-05-10

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Phase NA Completed

23 enrolled 8 charts

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT01046006 2021-04-30

Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

59 enrolled

Lymphoma, Waldenstrom Macroglobulinemia

NCT01125293 2021-04-23

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 1/2 Terminated

46 enrolled 29 charts

Waldenstrom Macroglobulinemia

NCT00422799 2020-10-27

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

63 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT01965977 2020-10-23

Borma

Phase 2 Unknown

59 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03515200 2020-09-01

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Terminated

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00182637 2020-08-03

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

5 enrolled 4 charts

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00093704 2020-07-31

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Phase 1 Terminated

1 enrolled

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoproliferative Disorders

NCT03617484 2020-06-22

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Phase 2 Withdrawn

Recurrence, Lymphoma, Mantle-Cell

NCT00992446 2020-03-18

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

27 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00440726 2020-02-19

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Phase 1/2 Completed

31 enrolled 15 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03390387 2020-02-05

ALL-MB 2015

Phase NA Unknown

4,000 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00980395 2019-12-30

VCR

24 enrolled 11 charts